FDA GLP-1 Compounding Crackdown: What's Happening and What to Do (2026)
If you’re on a compounded GLP-1 medication, you’ve probably seen alarming headlines about an FDA “crackdown” or “ban.” Some of it is real. A lot of it is overblown. This is the full picture.
What's Happening Right Now
On April 30, 2026, the FDA took three major actions targeting compounded GLP-1 medications:
The key point: This is a proposal, not a final rule. Compounded semaglutide and tirzepatide are still available through 503A pharmacies right now. But the regulatory environment is shifting fast, and you should understand what's at stake.
Timeline: How We Got Here
| Date | Event |
|---|---|
| 2022-2024 | Massive semaglutide/tirzepatide shortages; compounding pharmacies fill the gap |
| Feb 2025 | FDA ends semaglutide shortage — 503B facilities can no longer mass-produce it |
| Late 2024 | FDA ends tirzepatide shortage (but it returns to shortage list in 2025) |
| 2025 | Outsourcing Facilities Association sues the FDA — litigation ongoing |
| March 2026 | FDA signals stricter enforcement of compounding rules |
| April 30, 2026 | FDA proposes 503B removal, issues 30 warning letters, opens public comment |
| June 29, 2026 | Public comment period closes |
| July 2026 | Medicare GLP-1 Bridge program begins ($50/mo copay for Wegovy/Zepbound) |
| Late 2026 (est.) | Final rule expected after review of public comments |
| Jan 2027 | Medicare BALANCE Model expands GLP-1 coverage |
Where we are now: Between the proposal and the deadline. The public comment period is your chance to be heard.
503A vs 503B: Why This Distinction Matters
This is the single most important thing to understand about the crackdown. The FDA is going after 503B outsourcing facilities, not all compounding.
| 503A (Traditional Pharmacy) | 503B (Outsourcing Facility) | |
|---|---|---|
| Regulated by | State pharmacy boards | FDA (federal) |
| How they work | Individual prescription per patient | Bulk production, ships to clinics/offices |
| Affected by crackdown? | No — still operating | Yes — proposed removal from compounding list |
| Who uses them | Telehealth platforms (Eden Health, TrimRX, SkinnyRx) | Hospitals, large clinics |
| Current status | Legal with valid prescriptions | Restricted since Feb 2025; proposed permanent ban |
However: The FDA’s language has been increasingly broad. While the April 2026 proposal focuses on 503B facilities, future rulemaking could affect 503A pharmacies too. This is why the public comment period matters.
→ Full explainer on compounding legality
The 30 Warning Letters: Who Got Them and Why
The FDA’s 30 warning letters in April 2026 targeted:
- 503B facilities still compounding semaglutide — After the shortage ended in Feb 2025, these facilities were supposed to stop. Some didn't.
- Unlicensed operations — Companies compounding without proper state or federal registration
- False marketing claims — Operators claiming their compounded products were "FDA-approved" (they're not — no compounded product is)
- Overseas suppliers — Companies importing semaglutide from unregulated foreign sources
Who Was NOT Targeted #
- Licensed 503A pharmacies — Traditional compounding pharmacies with valid patient prescriptions
- Reputable telehealth platforms — Platforms using 503A pharmacies continue operating normally
- Patients — The FDA is not going after individuals using compounded medications
The pattern: The FDA is targeting bad actors — unlicensed operations, false claims, and facilities ignoring the rules. If you’re using a legitimate telehealth platform that works with a licensed 503A pharmacy, you’re not affected by these warning letters.
What to Do Now: 6 Action Steps
How to Submit a Public Comment (Step by Step)
The FDA is legally required to review public comments before finalizing any rule. High comment volume can influence the final decision — or at least shape how it’s implemented.
What to Include in Your Comment #
- How much you were quoted for brand-name GLP-1s without insurance
- Your insurance denial experience
- How compounded GLP-1s have affected your health (weight loss, A1C, blood pressure, etc.)
- What you would do if compounded options became unavailable
- Whether you can afford $900-1,400/month for brand-name alternatives
You don’t need to be an expert. The FDA values real patient experiences. A few sincere sentences about your situation are more impactful than a lengthy policy argument.
Frequently Asked Questions
Q: Did the FDA ban compounded semaglutide in April 2026?
No — not yet. The FDA proposed removing semaglutide and tirzepatide from the 503B bulk compounding list, but this is a proposal, not a final rule. A public comment period is open through June 29, 2026. 503A compounding pharmacies can still compound both medications with valid patient-specific prescriptions.
Q: What did the FDA warning letters say?
The FDA issued 30 warning letters targeting 503B outsourcing facilities still producing semaglutide after the shortage ended, unlicensed operations, and companies making false FDA-approval claims. Legitimate 503A pharmacies operating with valid patient prescriptions were not targeted.
Q: Can I still get compounded semaglutide right now?
Yes. 503A compounding pharmacies are still operating normally. Telehealth platforms like Eden Health, TrimRX, and SkinnyRx continue to offer compounded semaglutide and tirzepatide through licensed 503A pharmacies.
Q: Can 503A pharmacies still compound semaglutide?
Yes. The April 2026 crackdown primarily targets 503B outsourcing facilities. 503A traditional compounding pharmacies can still legally compound semaglutide and tirzepatide with valid patient-specific prescriptions from licensed providers.
Q: How do I submit a public comment to the FDA?
Visit regulations.gov and search for the FDA’s semaglutide/tirzepatide compounding proposal. Click “Comment” and share your personal experience — how compounded GLP-1s helped you, what would happen if access was restricted, affordability concerns. The comment period closes June 29, 2026.
Q: Will Medicare cover GLP-1s for weight loss?
Yes — the Medicare GLP-1 Bridge program begins July 2026, covering Wegovy and Zepbound at a $50/month copay under Part D. The broader BALANCE Model expands coverage starting January 2027.
Q: Is compounded tirzepatide affected by the crackdown?
Tirzepatide remains on the FDA shortage list as of April 2026, which gives compounding pharmacies broader authority to produce it. However, the FDA’s proposal would also remove tirzepatide from the 503B bulk compounding list if finalized. 503A pharmacies can still compound tirzepatide with valid prescriptions regardless.
Q: What happens if the proposal becomes final?
If finalized, 503B outsourcing facilities would be permanently barred from compounding semaglutide and tirzepatide. 503A pharmacies would likely still be able to compound with individual prescriptions, but the regulatory environment would be more restrictive. The final rule isn’t expected until late 2026 at the earliest.
Q: Should I switch to brand-name GLP-1s now?
Not necessarily. 503A compounding is still legal and available. If you want to explore brand-name options, check your insurance coverage (82% of denials are overturned on appeal) or consider LillyDirect for brand Zepbound at $299-449/month. If you’re on Medicare, the Bridge program starts July 2026.
The Bottom Line #
Compounded GLP-1s are still legal and available — but the regulatory landscape is changing.
The FDA's April 2026 actions are the most aggressive move yet against GLP-1 compounding. But right now, 503A pharmacies continue operating, and the proposed rule isn't final. Your most impactful action is submitting a public comment before June 29.
The three things to do today:
- Verify your telehealth platform uses a 503A pharmacy (they probably do)
- Submit a public comment at regulations.gov before June 29
- Know your backup options — insurance appeals, Medicare Bridge, LillyDirect
→ Compare telehealth platforms still offering compounded GLP-1s
Related Reading #
Questions? contact@glp1afterdenial.com
Last updated: May 5, 2026. This is an evolving situation — I'll update this page as new developments occur.
Affiliate Disclosure: Some links earn a small commission at no extra cost to you. I only recommend platforms I've personally researched. Sources: FDA.gov enforcement actions (April 2026), Federal Register proposed rulemaking, FDA Drug Shortage Database.